RT Journal Article
SR Electronic
T1 Point-of-care semiquantitative test for adherence to tenofovir alafenamide or tenofovir disoproxil fumarate
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.16.21262133
DO 10.1101/2021.08.16.21262133
A1 Sevenler, Derin
A1 Niu, Xin
A1 Dossantos, Sandy
A1 Toner, Mehmet
A1 Cressey, Tim R.
A1 Sandlin, Rebecca
A1 Drain, Paul
YR 2021
UL http://medrxiv.org/content/early/2021/08/24/2021.08.16.21262133.abstract
AB Objective Objective measurement of antiretrovirals may aid clinical interventions for improving adherence to HIV prevention or treatment regimens. A point-of-care urine test could provide real-time information about recent adherence to regimens containing tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF). We developed a lateral flow immunoassay (LFA) and enzyme-linked immunoassay (ELISA) for urinary tenofovir.Methods Intensity of the LFA test line was quantified using an optical reader and visually scored 0 – 5 by two independent people, using a reference card. The sensitivity and specificity of both the ELISA and LFA were determined for two different tenofovir concentration cutoffs for TDF and TAF adherence—1,500 ng/mL and 150 ng/mL, respectively. To validate the assays, we measured 586 urine samples from 28 individuals collected as part of a study of tenofovir pharmacokinetics in adults, which were also measured by mass spectrometry as ground truth.Results Both the LFA signal and ELISA signal were each strongly correlated to drug concentrations (0.91 and 0.92 respectively). The LFA signal and ELISA were highly sensitive and specific at both thresholds (LFA se/sp TDF 89%/96%, TAF 90%/96%; ELISA se/sp TDF 94%/94%, TAF 92%/84%). Visual scoring of the LFA was also highly sensitive and specific at both the TDF and TAF thresholds (se/sp TDF 91%/94%, TAF 87%/90%).Conclusions Our rapid semi-quantitative test can measure TFV concentrations relevant to both TAF or TDF adherence, which may support adherence-promoting interventions across a range of HIV care settings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by National Institutes of Health NIAID R01AI13664.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The testing of anonymized patient samples for this research was approved by the Institutional Review Board of Massachusetts General Hospital.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and generated in this study are administrated by the corresponding author and may be made freely available by reasonable request.